NLS Pharmaceutics Receives Nasdaq Staff Delisting Determination
NLS Pharmaceutics Ltd Strategizes for Growth
Board Member Resigns From NLS Pharmaceutics Ltd.
NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering
ZÜRICH, SWITZERLAND / ACCESSWIRE / March 22, 2024 / NLS Pharmaceutics Ltd. , a Swiss clinical-stage biopharmaceutical company focused on the
NLS Pharmaceutics Ltd. Announces New Warrant Issue
NLS Pharmaceutics Ltd. Addresses Financial Claims
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
ZURICH, SWITZERLAND / ACCESSWIRE / March 20, 2024 / NLS Pharmaceutics Ltd. , a Swiss clinical-stage biopharmaceutical company focused on the
NLS Pharmaceutics Expands Neurological Therapy Options
NLS Pharmaceutics Secures Exclusive Global License For Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform
NLS Pharmaceutics Secures Exclusive Global License For Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform
NLS Pharmaceutics Extends Loan Maturity Date
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event
ZURICH, SWITZERLAND / ACCESSWIRE / March 14, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discove
Nasdaq Accepts NLS Pharmaceutics' Plan to Regain Listing Compliance
ZURICH, SWITZERLAND / ACCESSWIRE / March 11, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discove
NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq
ZÜRICH, SWITZERLAND / ACCESSWIRE / February 23, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the dis
NLS Pharmaceutics Announced Nasdaq Letter Related To Continued Listing Requirements
NLS Pharmaceutics Announced Nasdaq Letter Related To Continued Listing Requirements
Notice of Deficiency With Nasdaq Continued Listing Requirements
ZURICH, SWITZERLAND / ACCESSWIRE / January 12, 2024 / NLS Pharmaceutics Ltd. , a Swiss clinical-stage biopharmaceutical company focused on the
NLS Pharmaceutics CEO Issues Letter to Shareholders
NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) today announces that its Chief Executive Officer, Alex Zwyer, has issued the following letter to shareholders.
Sector Update: Health Care Stocks Rise in Afternoon Trading
Health care stocks rose Friday afternoon with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each adding 0.3%. The iShares Biotechnology ETF (IBB) was up 0.7%. In corpora
Top Midday Gainers
Bit Brother (BETS) said it has purchased 3,300 units of Antminer S19 miners to boost its mining operations. Shares of the company surged 28%, with over 175 million shares traded intraday compared with
Altimmune ALT Phase 2 Data; NLS Pharmaceutics NLSP Options Agreement
NLS Pharmaceutics Signs Option Agreement to Acquire Rights to Aexon Labs' Assets; Shares Rise
NLS Pharmaceutics (NLSP) said Friday it has signed an exclusive option agreement under which it may acquire global development and commercialization rights to Aexon Labs' assets for the potential trea
No Data